5 February 2021 - Today, the Food and Drug Administration granted accelerated approval to umbralisib (Ukoniq, TG Therapeutics), a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon, for the following indications:

• Adult patients with relapsed or refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen
• Adult patients with relapsed or refractory follicular lymphoma who have received at least three prior lines of systemic therapy

Read FDA News